Cystic fibrosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CFTR 29
• GLP-1 2
• G6PD 0
• IL-13 0
• MUC1 0
• NF1 1
• PDE4 0
• STAT3 0
• CTNNB1 0
• DMD 1
• EGFR 0
• ERK 0
• HDAC 0
• HMGB1 0
• HTT 1
• IL-1 0
• IL-17 0
• IL-4 0
• IL-6 0
• mTOR 0
• NLRP3 0
• NRF2 0
• PKD1 0
• PPAR 0
• SGLT2 0
• SMN1 1
• TLR4 0

24 of 1,128 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Discovery and evolution of CRISPR-Associated Transposons (CAST) for functional RNA-guided integration (CRAFT)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €263,393· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines (LUNG-GENEMED)

  Politecnico di Milano· Milano, Italy· EU contribution €3,876,613· until Nov 2030· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Maternal human milk as a Risk factor to the Early-life Exposome (MATREEX)

  King's College London· London, United Kingdom· EU contribution €345,235· until Feb 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  In vitro and in situ structural characterization of the biofilm-associated functional amyloids in Pseudomonas aeruginosa bacteria (FAPbulous)

  Deutsches Elektronen-Synchrotron Desy· Hamburg, Germany· EU contribution €202,125· until Dec 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CellCourier: programmable drug delivery via combinatorial cell targeting and generative design of tailored binding peptides

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €150,000· until Jun 2027

  The disease is named only in the funder's project summary, not in the title.

5 of 11 running projects, newest first. Listed amounts together: €19.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

  NCT06603246· Genentech, Inc.· Updated 20 Oct 2026

  “Sponsor's Decision”Registry text, quoted unchanged. Source

• Suspended

  A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

  NCT07547436· Sanofi· Updated 29 Jul 2026

  “The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity.”Registry text, quoted unchanged. Source

• Withdrawn

  Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects

  NCT06339450· Centre Hospitalier Intercommunal Creteil· Updated 16 Jun 2026

  “Significant difficulties in recruiting participants, particularly in the 'cystic fibrosis' group.The constraints placed on participants, in particular the requirement to walk for ten days (5 days in an urban area and 5 days in a green area)”Registry text, quoted unchanged. Source

• Terminated

  MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis

  NCT03357562· University Hospital, Bordeaux· Updated 9 Jun 2026

  “Target number of inclusion not reached”Registry text, quoted unchanged. Source

• Withdrawn

  Effects of AD on VI in Patients With CF

  NCT03655249· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Updated 29 Apr 2026

  “No recruitement, no grant to support this study”Registry text, quoted unchanged. Source

• Terminated

  Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.

  NCT03312075· University Hospital, Brest· Updated 20 Mar 2026

  “The pace of patient enrollment was significantly affected by the COVID-19 pandemic. Since this is an epidemiological study that does not require a specific number of patients to meet the primary objective, the enrollment period was not extended.”Registry text, quoted unchanged. Source

• Terminated

  Diagnosis and Treatment of Patients With Cystic Fibrosis

  NCT00001223· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Updated 4 Feb 2026

  “PI left NIH”Registry text, quoted unchanged. Source

• Suspended

  Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

  NCT04306939· University of Pittsburgh· Updated 7 Jan 2026

  “Suspended for analysis and to consider further enrollment.”Registry text, quoted unchanged. Source

• Terminated

  Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease)

  NCT06399094· Groupe Hospitalier de la Region de Mulhouse et Sud Alsace· Updated 17 Nov 2025

  “Recruitment issue”Registry text, quoted unchanged. Source

• Terminated

  Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

  NCT05100823· University Hospital, Montpellier· Updated 18 Sept 2025

  “Enrolment period completed and sufficient number of enrolments to achieve study objectives”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Natural History of Bronchiectasis

  NCT00943514· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI

  NCT04391322· The Hospital for Sick Children· Source

• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· UCB Biopharma SRL· Source

• Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria

  NCT05686837· University of North Carolina, Chapel Hill· Source

• TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

  NCT07048574· State University of New York at Buffalo· Source

• Iron Repletion in Cystic Fibrosis

  NCT07903311· University of Michigan· Source

• Type 2 Inflammation in Adults With Cystic Fibrosis

  NCT07892443· University of Virginia· Source

• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· CSL Behring· Source

• A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Sanofi· Source

• Azithromycin to Modify Bronchiectasis Exacerbation Risk

  NCT07608328· Assiut University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 20
• CRISPR-Cas Systems 12
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 16
• Exome Sequencing 5
• Proteomics 12
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 2
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 21
• Machine Learning 6
• Deep Learning 3
• Cohort Studies 37
• Genome-Wide Association Study 3

• Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study.

  J Cyst Fibros, Jul 2026

• Cross-Disease Breathomics by PTR-TOF-MS: Multiclass Machine Learning and Network Remodeling Across Asthma, COPD, Cystic Fibrosis, and Lymphangioleiomyomatosis.

  Int J Mol Sci, Apr 2026

• Untargeted Metabolomic and Lipidomic Profiling in Cystic Fibrosis Patients Using UPLC-QTOF-MS.

  J Proteome Res, Mar 2026

• Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections.

  BMC Microbiol, Apr 2014

See which targets of this disease your abstract mentions, and go to the people working on them.